You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Patent: 10,072,098


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,072,098
Title:Pseudomonas aeruginosa PCRV binding single variable domain antibodies
Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the \"first\" immunoglobulin single variable domain and the \"second\" immunoglobulin single variable domain have different paratopes.
Inventor(s): De Tavernier; Evelyn (Deurle, BE), Union; Ann (Aalter, BE), Dombrecht; Bruno (Heusden, BE), Hermans; Guy (Merelbeke, BE), Morizzo; Erika (Ghent, BE)
Assignee: Ablynx N.V. (Ghent-Zwijnaarde, BE)
Application Number:14/382,027
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,072,098

Introduction

Understanding the intricacies of a patent, particularly one like United States Patent 10,072,098, involves a deep dive into its claims, the patent landscape, and the legal frameworks that govern its validity and enforceability. This analysis will cover key aspects such as the subject matter eligibility, obviousness and novelty, patent term adjustments, and the strategic use of patent file wrappers for competitive intelligence.

Subject Matter Eligibility Under 35 U.S.C. § 101

When evaluating the patentability of claims under United States Patent 10,072,098, it is crucial to consider the subject matter eligibility criteria outlined in 35 U.S.C. § 101. The Supreme Court's decision in Alice Corp. v. CLS Bank International and subsequent guidance from the USPTO emphasize a two-pronged framework for determining eligibility.

Prong One: Abstract Idea

The first prong involves determining whether the claims are directed to an abstract idea. If the claims do not recite an abstract idea, they are patent-eligible. However, if they do, the analysis proceeds to Prong Two[3].

Prong Two: Practical Application

Under Prong Two, the claims must integrate the abstract idea into a practical application. This can be demonstrated by showing that the claims reflect an improvement in the functioning of a computer or another technical field. For AI inventions, for example, the 2024 Guidance Update highlights the importance of demonstrating a specific, concrete technological advancement or solution to a technical problem[3].

Obviousness and Novelty (35 U.S.C. § 102 and § 103)

The patentability of claims also hinges on their novelty and non-obviousness.

Prior Art Analysis

The examiner must review prior art to determine whether the claims are novel and non-obvious. This process is iterative, with the applicant potentially narrowing or limiting the scope of the claims to overcome rejections based on prior art. For instance, if a claim is rejected under 35 U.S.C. § 102(a)(1) or § 102(a)(2) as being anticipated by prior art, the applicant must argue or amend the claims to distinguish them from the prior art[4].

Obviousness-Type Double Patenting (ODP)

ODP is another critical consideration, particularly when dealing with patents that have been granted Patent Term Adjustments (PTA) or Patent Term Extensions (PTE). The Federal Circuit has held that ODP analyses should be based on the adjusted expiration date of the patent, taking into account any PTA or PTE granted. This ensures that an inventor cannot secure a second, later-expiring patent for an invention covered by a previously granted patent with a different patent term due to PTA or PTE[1].

Patent Term Adjustments and Extensions

Patent term adjustments and extensions can significantly impact the lifespan of a patent.

Patent Term Adjustments (PTA)

PTA is granted to compensate for delays in the patent prosecution process. The USPTO adjusts the patent term by one day for each day the office fails to meet certain response deadlines. However, the Federal Circuit has clarified that PTA does not extend the term of a patent past the date of a terminal disclaimer, which is often used to overcome ODP rejections[1].

Patent Term Extensions (PTE)

PTE, on the other hand, is granted under specific circumstances, such as delays due to regulatory review. The Federal Circuit has held that PTE is calculated from the expiration date resulting from a terminal disclaimer, if any, and not from the date the patent would have expired in the absence of the terminal disclaimer[1].

Using Patent File Wrappers for Competitive Intelligence

Patent file wrappers are invaluable tools for competitive intelligence and technology landscape analysis.

Insights from Prosecution History

Reviewing the file wrapper of a patent like 10,072,098 provides context into the arguments made by the examiner and the applicant during the prosecution process. This includes understanding which prior art was cited, how the applicant overcame rejections, and any amendments made to the claims. Such insights can help competitors or potential licensees understand the strengths and weaknesses of the patent[4].

Strategic Decision-Making

Access to this information can be particularly empowering when making investment decisions or assessing the validity of a patent. By analyzing the prosecution history, one can gain a deeper understanding of the patent's scope and potential vulnerabilities, which can inform strategic decisions such as whether to challenge the patent or negotiate licensing terms[4].

Crafting Effective Arguments

When facing rejections or challenges to patent claims, it is crucial to craft effective arguments that address the examiner's concerns.

Understanding the Examiner's Perspective

Different patent examiners may apply the subject matter eligibility framework differently. Understanding how the assigned examiner approaches these analyses can help applicants tailor their arguments to be more persuasive. For example, some examiners may focus more on improvements to computer functionality, while others may consider improvements to other technical fields[3].

Balancing Prong One and Prong Two Arguments

Applicants should balance their arguments between Prong One and Prong Two of the subject matter eligibility analysis. While detailed legal arguments under Prong One are necessary, they should not overshadow the more persuasive technological improvement and practical application arguments under Prong Two[3].

Key Takeaways

  • Subject Matter Eligibility: Ensure claims integrate abstract ideas into practical applications to overcome § 101 rejections.
  • Obviousness and Novelty: Carefully distinguish claims from prior art to satisfy § 102 and § 103 requirements.
  • Patent Term Adjustments: Understand how PTA and PTE affect the patent term, especially in relation to ODP analyses.
  • Competitive Intelligence: Utilize patent file wrappers to gain insights into the prosecution history and strategic vulnerabilities of a patent.
  • Effective Arguments: Tailor arguments to the examiner's perspective and balance legal and technological aspects.

FAQs

Q1: What is the significance of Prong Two in the subject matter eligibility analysis? Prong Two is crucial as it requires demonstrating that the claims integrate the abstract idea into a practical application, showing an improvement in computer functionality or another technical field.

Q2: How does ODP affect patents with PTA or PTE? ODP analyses must be based on the adjusted expiration date of the patent, considering any PTA or PTE granted, to prevent an inventor from securing a second, later-expiring patent for the same invention.

Q3: What can be learned from reviewing a patent's file wrapper? Reviewing a patent's file wrapper provides insights into the prosecution history, including prior art cited, arguments made, and amendments to claims, which can inform strategic decisions.

Q4: Why is it important to understand the examiner's perspective in patent arguments? Understanding the examiner's perspective helps applicants tailor their arguments to be more persuasive, as different examiners may apply the subject matter eligibility framework differently.

Q5: How should applicants balance their arguments between Prong One and Prong Two? Applicants should ensure that detailed legal arguments under Prong One do not overshadow the more persuasive technological improvement and practical application arguments under Prong Two.

Sources

  1. In re Cellect, LLC, United States Court of Appeals for the Federal Circuit, 2023.
  2. Amicus Brief, Supreme Court of the United States, 2023.
  3. The Importance of Prong Two of Step 2A for AI Inventions, Baker Botts, 2024.
  4. Patent File Wrappers as a Tool for Competitive Intelligence, IP Checkups, 2023.

More… ↓

⤷  Subscribe

Details for Patent 10,072,098

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 October 21, 1942 ⤷  Subscribe 2032-03-02
Takeda Pharmaceuticals U.s.a., Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 March 03, 1954 ⤷  Subscribe 2032-03-02
Csl Behring Ag ALBURX albumin (human) Injection 102366 July 23, 1976 ⤷  Subscribe 2032-03-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.